Hetero presents positive results from Molnupiravir phase III trials

Hyderabad: Hyderabad-based Hetero unveiled results of phase III trials of Movfor (Molnupiravir), an investigational oral antiviral Covid-19 drug. The company demonstrated that Molnupiravir along with Standard of Care (SOC) reduced the risk of hospitalisation by over 65 per cent compared to SOC alone. The results were presented as an oral abstract at the Conference on […]

Hyderabad: Hyderabad-based Hetero unveiled results of phase III trials of Movfor (Molnupiravir), an investigational oral antiviral Covid-19 drug. The company demonstrated that Molnupiravir along with Standard of Care (SOC) reduced the risk of hospitalisation by over 65 per cent compared to SOC alone.

The results were presented as an oral abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12–16, 2022,

---

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study.

Under the phase III trials, one of the studies included 1,218 Covid-19 patients (with SPO2>93% and Covid-19 symptoms as per ICMR Covid-19 guidelines). The study enrolled eligible patients, within five days of symptom onset, and were administered with Molnupiravir capsules (800 mg twice daily) SOC or SOC alone for five days.

Hetero entered into a non-exclusive voluntary licensing agreement with MSD in April 2021 for the manufacturing and distribution of investigational oral therapeutic antiviral drug ‘Molnupiravir’ for the treatment of Covid-19.

Under this licensing deal, Hetero was allowed to expand access of Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorisation by local regulatory agencies.

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .

---